At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PULM Pulmatrix
Post-Mkt 09-30 17:37:02 EDT
1.52
-0.04
-2.38%
盘后1.52
+0.000.00%
16:20 EDT
High1.58
Low1.50
Vol8.44K
Open1.54
D1 Closing1.56
Amplitude5.13%
Mkt Cap5.55M
Tradable Cap5.51M
Total Shares3.65M
T/O12.91K
T/O Rate0.23%
Tradable Shares3.63M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Pulmatrix Sets Special Meeting to Approve Merger With Eos SENOLYTIX
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.